- Company
- Minjung Jung to head Corporate Affairs at Sanofi KR, NZ, AU
- by Eo, Yun-Ho Sep 26, 2024 05:51am
- Sanofi’s Executive Director Minjung Jung (48) has been named head of Corporate Affairs for the Sanofi Group's 3 subsidiaries - Korea, New Zealand, and Australia. The appointment follows the appointment of Kyungeun Bae (53) as the General Manager of Pharma MCO South Korea and Australia/New Zealand & MCO Lead in the first half of last year
- Company
- "Bird flu: a new emerging pandemic risk factor"
- by Son, Hyung Min Sep 25, 2024 05:49am
- The industry is preparing against avian influenza, which can be transmitted from animal to human, as it is predicted to be the next pandemic risk factor. Experts suggest that an improved vaccine technology development and manufacturing system are required ahead of the emerging pandemic following COVID-19. CSL Seqirus Korea held a press co
- Company
- ‘Link the processes to improve access to orphan drugs'
- by Kim, Jin-Gu Sep 25, 2024 05:49am
- A claim has been raised that the approval, evaluation, and negotiation linkage system should be introduced to strengthen access to rare disease drugs. Also, the claim that the pharmacoeconomic evaluation system should be flexibly applied to rare disease drugs and that the scope of the risk-sharing agreement system be expanded was raised at the t
- Company
- Cancer mRNA vaccine shows potential in brain tumor
- by Son, Hyung Min Sep 24, 2024 05:46am
- Therapeutic cancer vaccines have been showing promise in central nervous system diseases. CureVac recently confirmed the safety of its messenger ribonucleic acid (mRNA) vaccine, CVGBM, in glioblastoma in a Phase I clinical trial. Immunomic Therapeutics and IM Biologics have also taken up the challenge of developing cancer vaccines for brain
- Company
- 'Keytruda' attempts at reimbursement for TNBC
- by Whang, byung-woo Sep 24, 2024 05:46am
- The industry watches whether Keytruda (pembrolizumab), which demonstrated treatment benefits in early triple-negative breast cancer, will pass the reimbursement hurdle. As the Cancer Disease Review Committee (CDRC) of the Health Insurance Review and Assessment Service (HIRA) convenes in October, whether Keytruda will set a ground to expand 17
- Company
- Samsung Bioepis’ Opuviz recommended for approval in Europe
- by Whang, byung-woo Sep 24, 2024 05:46am
- Samsung Bioepis announced on the 23rd that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the company’s Eylea biosimilar ‘Opuviz (aflibercept).’ The EMA CHMP’s positive opinion plays a crucial role in the marketing authorization review process by the Euro
- Company
- Will Wegovy launch in KOR continue the Saxenda syndrome?
- by Moon, sung-ho Sep 24, 2024 05:46am
- 'Wegovy,' an obesity drug that is hugely popular but in shortages worldwide, will land in South Korea in mid-October. It will become domestically available a year and a half after receiving approval from the Ministry of Food and Drug Safety (MFDS). It marks the ninth release worldwide, following Japan and China. The Wegovy effect has garn
- Company
- Severe asthma biologic 'Nucala' available in the 'Big 5'
- by Eo, Yun-Ho Sep 24, 2024 05:46am
- The biologic antibody drug 'Nucala' is now available for prescription at tertiary general hospitals. According to industry sources, GSK's Nucala (mepolizumab), a treatment for severe neutrophilic asthma, has passed the drug committees of the 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul As
- Company
- Hugelsets sights on Indonesia with botulinum toxin Letybo
- by 어윤호 Sep 23, 2024 09:40am
- Hugel Inc., a leading global medical aesthetics company, said on Monday it had hosted a launch event of Letybo last week at Shangri-La Jakarta in Indonesia, the second-largest medical aesthetics market in Southeast Asia, to promote the clinical efficacy of the botulinum toxin. The event comprised online and on-site lectures on techniques a
- Company
- Why royalties for Yuhan’s Leclaza were reduced $300mil
- by Chon, Seung-Hyun Sep 23, 2024 05:51am
- The maximum contract amount for Leclaza, which was licensed out to Janssen by Yuhan Corp, has been reduced by USD 350 million. This reduction was due to the termination of research to develop Leclaza as a next-generation anti-cancer drug. Yuhan Corp received USD 210 million as upfront payment and development and approval milestones for the licen
